TheStreet's Jim Cramer says some biotech companies could be in play after the end of the deal between Pfizer (PFE) and Allergan (AGN) , adding that Gilead (GILD) could potentially buy Allergan. Cramer also added that Celgene (CELG) could be in play. Cramer also said that after Allergan, Johnson & Johnson (JNJ) has the best growth among the old line pharma stocks. Cramer added it looks like biotech has bottomed. Cramer, who's portfolio manager of Action Alerts PLUS, also discussed Target (TGT) , Southern Company (SO) and AEP (AEP) on the floor of the New York Stock Exchange Wednesday. Viewers can send their questions to Cramer on his Facebook page or on Twitter, use hashtag CramerQ.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.